Hereditary Cancer (CGx)
A Cancer Genetic Test (CGx) identifies specific inheritable gene mutations that may elevate a patient's risk of cancer development or recurrence. This comprehensive test analyzes critical genes and tumor markers, including BRCA1, BRCA2, ATM, COH1, MLH1, HSH2, MSH6, and PTEN. If a pathogenic variant is detected, close relatives (such as children, siblings, and parents) face an increased risk, with the likelihood of up to 8 times greater susceptibility.
Cardiovascular Disease (CardioGX)
Inherited heart conditions, originating from genetic mutations, are often passed down through families. These conditions manifest as changes (mutations) in one or more genes of a patient. They encompass a range of conditions, including:
Pharmacogenetics (PGX)
Pharmacogenetics testing (PGX) examines how a patient's body metabolizes drug enzymes, offering invaluable insights into the efficacy and safety of medications. This study focuses on understanding individual responses to drug therapy based on their genetic makeup.
Parkinson's-Alzheimer's-Dementia (PAD)
Genetic factors significantly contribute to the development of conditions such as Parkinson's disease, Alzheimer's disease, and certain genetic disorders leading to dementia. Individuals with a family history of these conditions, especially a parent or sibling with Alzheimer's, face an elevated risk. Genetic testing can determine the presence of specific risk-associated genes.
Primary Immunodeficiency
Primary immunodeficiencies encompass a wide array of hereditary or genetic disorders that impede the normal functioning of immune system cells, rendering patients vulnerable to infections.
Diabetes-Obesity
Patients exhibiting signs of monogenic diabetes and obesity-related disorders, whether independently or as features of a genetic syndrome, may benefit from genetic testing. If a pathogenic variant is identified in a patient, close relatives (children, siblings, and parents) could be up to 50% more likely to face increased risks.